Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zenapax in Multiple Sclerosis
NCT00001934Phase 2Completed
- Sponsor
- National Institute of Neurological Disorders and Stroke
- Start
- Sep 1999
- Primary completion
- Aug 2005
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of daclizumab in multiple sclerosis (MS), sponsored by National Institute of Neurological Disorders and Stroke. Started Sep 1999; status: completed.
02
Drugs
daclizumab
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT00001934.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00001934.